- Home
- SCNX vs VTGN Comparison
SCNX vs VTGN Comparison
Compare SCNX & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNX | VTGN |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | 19 | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0M | 21.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | SCNX | VTGN |
|---|---|---|
| Price | $0.31 | $0.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $1.50 | $0.90 |
| AVG Volume (30 Days) | ★ 2.5M | 417.5K |
| Earning Date | 05-11-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | $347.88 | $124.49 |
| Revenue Next Year | $744.44 | $353.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.24 | $0.43 |
| 52 Week High | $2.60 | $5.14 |
Technical Indicators
Market Signals| Indicator | SCNX | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 34.81 | 45.48 |
| Support Level | N/A | $0.57 |
| Resistance Level | $0.48 | $0.60 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 22.90 | 35.85 |
Price Performance
Historical ComparisonAbout SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.